



Indoco Remedies Limited

COMPANY BACKGROUND.....

- In 1945, Late Mr. Govind Ramnath Kare founded 'Indo-Continental Trading Company', to import pharmaceutical products from Europe, and after independence it ventured into the manufacturing of pharmaceuticals to foster manufacturing of indigenous pharmaceutical formulations, thus, creating Indoco Remedies Limited.
- Indoco Remedies Ltd (Indoco) is an integrated, research-oriented pharmaceutical company with seven decades of presence in Indian markets and a strong international presence.
- The company is primarily engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs).
- It has 9 manufacturing facilities in India, 6 for finished dosages and 3 for API's, which is supported by a 1,00,000 sq.ft. state-of-the-art R&D Centre and a 150 Bed Clinical Research Organization (CRO).
- The manufacturing facilities are approved by various regulatory authorities including USFDA, UK-MHRA and TGA-Australia.
- Indoco has a large basket of products backed by ANDAs / eCTD dossiers and Drug Master Files (DMFs).

BUSINESS MIX (as on Q2-FY25).....

- **Domestic Formulations (55%):** Indoco's domestic formulations business has a pan India presence. Indoco has a strong presence in the Indian market and is rated highly by the key customers and Doctors across the country.
- **International Formulations(36%):** For the international markets, Indoco offers complete solutions, including product development, manufacture and supply of finished dosages, APIs and intermediates. Indoco has a strong foothold in the international market with exports to over 55 countries
- **Active Pharmaceutical Ingredient(8%):** Indoco offers full range of services with respect to API supplies in Regulated markets. The distinct advantage of API business emanates from the backward integration for its own ANDAs and Dossiers as well.
- **Allied Services(1%):** AnaCipher CRO (state-of-the-art clinical research facility), Indoco Analytical Solutions (USFDA Approved cGMP Laboratory), Xtend Industrial Designers & Engineers Pvt. Ltd (engineering and consulting services for all phases of project development, from project design to product validation)

FINANCIAL PERFORMANCE (CONSOLIDATED)

(INR Mn)	Operating Income	EBITDA	EBITDA%	PAT	PAT%	EPS
FY22	15,408	3,273	21.25%	1,548	10.05%	16.80
FY23	16,686	2,861	17.15%	1,423	8.53%	15.42
FY24	18,173	2,443	13.44%	970	5.34%	10.51
H1-FY25	8,641	880	10.18%	(82)	(0.95)%	(0.89)

Note: All numbers are as per IND-AS

Key Data

BSE Code	532612
NSE Code	INDOCO
Reuters	INRM.BO
Bloomberg	INDR:IN

Market Data (INR) as on 30th September, 2024.

Face Value	2.0
CMP	359.2
52 Week H/L	417.0/286.5
MCAP (Mn)	33,111.9
Shares O/S (Mn)	92.2
Avg. Volume ('000)	176.72

Performance as on 30th September, 2024.

	3M	6M	12M
Indoco Remedies LTD.	10.49%	9.31%	1.48%
SENSEX	6.65%	13.97%	28.09%
BSE SMALLCAP	9.02%	31.18%	51.58%

Shareholding Pattern as on 30th September, 2024.

Promoters	59.04%
Public	20.93%
DII	18.33%
FII	1.70%


INDIA Business (FY24).....

Acute – 88%	Chronic – 12%
-------------	---------------

Domestic Formulations - H1/FY25

Major Therapeutic Segments Contribution (Q2-FY25).....


Major Therapeutic Segments	Revenue Share
Stomatologicals	24%
Gastro - Intestinal	17%
Respiratory	14%
Anti – Infectives	17%
Others	28%



Top Brands & their revenue share (Q2-FY25).....

Top Brands	Market Share
Cyclopam	15%
Febrex Plus	8%
Oxipod	7%
Cital	7%
ATM	6%
SENSOFORM	3%

International Formulations – H1/FY25



■ Regulated Markets (US, Europe, SA, Others)

■ Emerging Markets (FWA, Asia, Africa, LATAM, Others)

KEY GROWTH DRIVERS.....

Domestic Formulations:

- Expand in Northern and Eastern regions.
- Strategic in-licensing in chronic segment.
- Focusing on sales force effectiveness, new product launches & exploring new channels of distribution.
- Strategic focus on sub-chronic category to enhance prescription from mass specialists (pediatrician, ENT, ophthalmologist, dentist, gynecologist) to drive favorable mix.
- Selective launches in specialty segment.

International Formulations:

- Drive operational efficiency.
- Transition to complete in-house distribution in the US.
- EU-GMP compliance for Goa plant-1 and Baddi plant-3 led larger available capacity and launch of proprietary products will help drive EU business.
- Robust pipeline of specialty dosages (ophthalmic and injectable).
- Curb other expenses.
- Strong customer base makes the Company, a preferred partner, offering complete solutions to its customers worldwide.

API & Allied Services:

- Expertise in Research and Development.
- Backward integration with own APIs.
- Full-fledged CRO set-up.

PEER COMPARISON (TRAILING 12 MONTHS) INR MN

Company	Operating Income	Operating EBITDA	Operating EBITDA%	PAT	PAT%	Market Cap
Indoco Remedies	17,733	1,999	11.27%	294	1.66%	28,346
Glenmark	1,22,477	14,859	12.13%	-8,504	-6.94%	4,69,984.
Gland Pharma	58,902	12,766	21.67%	6,916	11.74%	2,93,415
Cipla	2,65,120	66,648	25.14%	44,808	16.90%	12,85,434
Sun Pharma	5,03,078	1,40,586	27.95%	1,11,308	22.13%	43,46,035

INCOME STATEMENT (CONSOLIDATED)

PARTICULARS (INR Mn)	FY22	FY23	FY24	H1-FY25
Operational Income	15,408	16,686	18,173	8642
Operating Expenses	12,134	13,825	15,730	7,761
EBITDA	3,273	2,861	2,443	880
EBITDA Margins (%)	21.25%	17.15%	13.44%	10.18%
Depreciation and amortisation	790	706	919	564
Finance costs	141	250	380	321
Other Income	23	23	99	26
Exceptional Items	-	-	115	-
PBT	2,366	1,928	1,358	21
Tax Expense	818	505	388	103
PAT	1,548	1,423	970	-82
PAT Margins (%)	10.05%	8.53%	5.34%	(0.95)%
Other Comprehensive Income	(53)	14	3	(11)
Total Comprehensive Income	1,495	1,437	973	93
Diluted EPS	16.80	15.42	10.51	(0.89)

CONSOLIDATED BALANCE SHEET (IND-AS).....

PARTICULARS (INR MN)	FY23	FY24	H1-FY25	PARTICULARS (INR MN)	FY23	FY24	H1-FY25
EQUITY	10,283	11,105	10,889	NON-CURRENT ASSETS	8,446	11,900	13,551
Equity Share Capital	184	184	184	a) Property, plant and equipment	5,952	7,726	7,828
Other Equity	10,099	10,915	10711	b) Capital work-in-progress	553	1,029	2,295
Non-controlling interest	-	6	-6.6	c) Right of Use Assets	170	156	145
NON-CURRENT LIABILITIES	2,054	4,219	5,002	d) Other Intangible assets	660	1,446	1,298
a) Financial Liabilities				e) Intangible assets Under Development	582	219	352
i) Borrowings	1,435	3,517	4324	f) Goodwill On Consolidation	1	215	215
ii) Lease Liability	150	124	106	g) Financial assets			
iii) Other Financial Liabilities	-	48	51	i) Investments	15	15	15
b) Provisions	334	337	311	ii) Loans	29	31	32
c) Deferred tax liabilities (net)	61	118	136	iii) Other Financial Assets	20	67	70
d) Other Non- Current Liabilities	74	75	74	h) Income Tax Assets (Net)	-	-	
CURRENT LIABILITIES	4,245	6,123	8,007	l) Other non-current assets	465	996	1,301
a) Financial Liabilities				CURRENT ASSETS	8,136	9,547	10,347
i) Borrowings	1,710	3,034	3865	a) Financial Assets			
ii) Lease Liabilities	33	44	49	i) Investment	10	72	126
iii) Trade Payables	1,235	1,536	2,415	ii) Trade Receivables	3,509	4,062	3,819
iv) Other financial liabilities	576	880	1,044	iii) Cash and cash equivalents	109	149	182
b) Other current liabilities	196	145	202	iv) Bank balances other than above	24	95	110
c) Provisions	495	484	432	v) Loans	7	15	15
d) Income Tax Liabilities(Net)	-	-	-	vi) Other financial assets	30	70	28
TOTAL LIABILITIES	6,299	10,342	13,001	b) Other current assets	1,132	1,536	88
TOTAL EQUITY AND LIABILITIES	16,582	21,447	23,898	c) Inventories	3,260	3,531	3,827
				d) Current tax Assets (Net)	55	17	2,152
				TOTAL ASSETS	16,582	21,447	23,898

INVESTOR RELATIONS TEAM AT VALOREM ADVISORS

Name	Designation	Email	Phone
Anuj Sonpal	CEO	anuj@valoremadvisors.com	+91-22-4903-9500
Sumeet Singhania	Lead Manager	sumeet@valoremadvisors.com	+91-22-4903-9500

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This factsheet has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

Indoco Remedies Limited Disclaimer:

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be “forward looking statements” based on the currently held beliefs and assumptions of the management of Indoco Remedies Limited, which are expressed in good faith and in their opinion reasonable, including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company’s business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.

This document is confidential and may not be copied or disseminated, in whole or in part, and in any manner.